文献速递眼底病与葡萄膜炎

低剂量阿司匹林对年龄相关性黄斑变性病程的影响:ASPREE随机临床试验的二次分析

Effect of Low-Dose Aspirin on the Course of Age-Related Macular Degeneration: A Secondary Analysis of the ASPREE Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

ASPREE-AMD是ASPREE试验的澳大利亚亚组研究,纳入4993名70岁及以上无痴呆、无心血管疾病等限制寿命疾病的参与者,随机接受阿司匹林100 mg每日肠溶片或安慰剂。分析3171名有随访视网膜影像者,中位随访3.1年,阿司匹林组与安慰剂组AMD累积发病率分别为19.4%与19.1%(RR 1.02,95%CI 0.85-1.22,P=0.86),早期/中期进展为晚期AMD分别为2.3%与3.1%(RR 0.72,95%CI 0.36-1.44,P=0.36)。结论认为每日低剂量阿司匹林持续3年不影响AMD发病率,因进展病例数少,对进展的证据较弱,总体结果不支持每日低剂量阿司匹林可预防AMD发生或进展。

要点

  • 每日阿司匹林100 mg持续约3年未影响年龄相关性黄斑变性(AMD)的累积发病率(19.4% vs 19.1%,RR 1.02,P=0.86)。
  • 早期/中期AMD进展为晚期AMD在阿司匹林组为2.3%、安慰剂组为3.1%,RR 0.72(95%CI 0.36-1.44,P=0.36),未达统计学显著。
  • 因进展病例数少,关于AMD进展的证据较弱,总体结果不支持每日低剂量阿司匹林预防AMD发生或进展。

核心结论

  • 每日低剂量阿司匹林持续3年不影响AMD的发病率。
  • 因进展病例数少,阿司匹林对AMD进展的证据较弱。
  • 总体结果不支持每日低剂量阿司匹林可预防AMD发生或进展。

研究设计与样本

  • ASPREE-AMD是ASPREE试验的澳大利亚亚组研究,ASPREE为多中心、国际、随机、双盲、安慰剂对照临床试验。
  • 纳入70岁及以上、无痴呆、无限制独立生活的躯体残疾、无心血管疾病、无限制5年生存的慢性病且基线视网膜影像可分级者。
  • 共4993名参与者入组,随机接受阿司匹林100 mg每日肠溶片或安慰剂。
  • 基线视网膜摄影于2010年3月至2015年1月进行,随机化后3年和5年复查。
  • 3208名有视网膜随访数据,其中3171名纳入AMD发病与进展分析,中位(IQR)年龄73.5(71.5-76.4)岁,女性1619名(51%),中位(IQR)随访3.1(3.0-3.5)年。

主要发现

  • AMD累积发病率:阿司匹林组195/1004(19.4%) vs 安慰剂组187/979(19.1%),RR 1.02(95%CI 0.85-1.22,P=0.86)。
  • 早期/中期进展为晚期AMD:阿司匹林组14/615(2.3%) vs 安慰剂组18/573(3.1%),RR 0.72(95%CI 0.36-1.44,P=0.36)。
  • 两组基线特征相似。

关键数值与推荐

  • AMD发病:阿司匹林组195/1004(19.4%) vs 安慰剂组187/979(19.1%),RR 1.02(95%CI 0.85-1.22,P=0.86)。
  • AMD进展:阿司匹林组14/615(2.3%) vs 安慰剂组18/573(3.1%),RR 0.72(95%CI 0.36-1.44,P=0.36)。

临床怎么用

  • 原文结论为总体结果不支持每日低剂量阿司匹林可预防AMD发生或进展。

局限性

  • 因进展病例数少,关于AMD进展的证据较弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in old age. There is no proven intervention to prevent AMD and, apart from lifestyle, nutritional, and supplement advice, there is no intervention to delay its progression. OBJECTIVE: To determine the impact of long-term low-dose aspirin on the incidence and progression of AMD. DESIGN, SETTING AND PARTICIPANTS: The Aspirin in Reducing Events in the Elderly-AMD (ASPREE-AMD) study was an Australian-based substudy of the ASPREE trial, a multicenter, international, randomized, double-masked, placebo-clinical trial investigating the efficacy of low-dose aspirin in prolonging disability-free survival among older individuals. Retinal photography was conducted at baseline from March 2010 to January 2015, then 3 and 5 years after randomization. AMD status was determined using color retinal images and treatment records. Australian participants in ASPREE aged 70 years and older without dementia, independence-limiting physical disability, cardiovascular disease, or chronic illness limiting 5-year survival and with gradable retinal images at baseline were included. Data were analyzed from December 2022 to December 2023. INTERVENTIONS: Aspirin (100 mg daily, enteric coated) or placebo. MAIN OUTCOMES AND MEASURES: Incidence of AMD and progression from early/intermediate to late AMD. Outcomes were analyzed by modified intention-to-treat analysis. RESULTS: A total of 4993 participants were enrolled in this substudy. Baseline characteristics were similar between groups. At the time of sponsor-determined trial termination, retinal follow-up data were available for 3208 participants, 3171 of whom were analyzed for AMD incidence and progression, with a median (IQR) age of 73.5 (71.5-76.4) years and even sex distribution (1619 [51%] female). Median (IQR) follow-up time was 3.1 (3.0-3.5) years. Cumulative AMD incidence was 195 of 1004 (19.4%) in the aspirin group and 187 of 979 (19.1%) in the placebo group (relative risk [RR], 1.02; 95% CI, 0.85-1.22; P = .86). Cumulative progression from early/intermediate AMD to late AMD was observed in 14 of 615 (2.3%) participants in the aspirin group and 18 of 573 (3.1%) in the placebo group (RR, 0.72; 95% CI, 0.36-1.44; P = .36). CONCLUSIONS AND RELEVANCE: In this trial, low-dose aspirin administered for 3 years did not affect the incidence of AMD. The evidence was weaker for progression of AMD due to low number of progressed cases. Overall, these results do not support suggestion that low-dose daily aspirin prevents the development or progression of AMD. TRIAL REGISTRATION: anzctr.org Identifier: ACTRN12613000755730.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Robman LD, Wolfe R, Woods RL, et al. Effect of Low-Dose Aspirin on the Course of Age-Related Macular Degeneration: A Secondary Analysis of the ASPREE Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 38780931. doi:10.1001/jamaophthalmol.2024.1584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。